Lactobacillus fermentum – LF10 (DSM 19187)

     

    Gynecology blend | Vaginal candidiasis

    • Lactobacillus acidophilus – LA02 (DSM 21717)
    • Lactobacillus fermentum – LF10 (DSM 19187)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    1,2) 400 million CFU/strain/tablet + Carbon dioxide + FOS + Arabinogalactan

    FUNCTIONALITY
    Vaginal health • Inhibition of Candida strains • Innovative effervescent slow release tablet for enhanced delivery and activity of lactobacilli • Counteraction of Candida vulvovaginitis

    Scientific support

    Human clinical trials
    1) Vicariotto F. et al. Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. J Clin Gastroenterol. 2012; 46 Suppl:S73-80.
    2) Murina F. et al. Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a Slow-release Vaginal Product be Useful for Prevention of Recurrent Vulvovaginal Candidiasis? J Clin Gastroenterol. 2014; 48:S102-105.

    In vitro study
    Deidda F. et al. The In Vitro Effectiveness of Lactobacillus fermentum Against Different Candida Species Compared With Broadly Used Azoles. J Clin Gastroenterol. 2016; 50:S171-S174.


    Gynecology blend | Vaginal candidiasis

    • Lactobacillus plantarum – LP02 (LLMG P-21020)
    • Lactobacillus fermentum – LF10 (DSM 19187)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    500 million per strain

    FUNCTIONALITY
    Vaginal health • Counteraction of Candida vulvovaginitis • Counteraction of Candida vulvovaginitis including recurrence

    Scientific support

    Clinical study
    Murina F. et al. Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. New Microbiologica, 41,3, 220-224, 2018, ISN 1121-7138.


    Gut-brain blend | ALS

    • Lactobacillus fermentum – LF10 (DSM 19187)
    • Lactobacillus delbrueckii subsp. delbrueckii – LDD01 (DSM 22106)
    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus salivarius – LS03 (DSM 22776)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    LF10 4 billion cfu + LDD01 2 billion cfu + LP01 2 billion cfu + LS03 2 billion cfu

    Scientific support

    Human clinical trial
    Mazzini L. et al. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies. J Clin Gastroenterol, Vol 00, N 00, 2018.
    Clinical studies on-going